Metropolis Healthcare · NSE: METROPOLIS · BSE: 542650
Q4 FY25 results · Jan–Mar 2025
Metropolis Healthcare reported revenue from operations of ₹345.29 crore (up 4.3% from Q4 FY24) and net profit of ₹29.23 crore (down 20.0% from Q4 FY24) for Q4 FY25 (Jan–Mar 2025), on a consolidated basis.
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 345.29 | 331.00 | +4.3% | 322.77 | +7.0% |
| Other income | 6.97 | 2.54 | +174.5% | 2.56 | +172.8% |
| Total income | 352.26 | 333.54 | +5.6% | 325.32 | +8.3% |
| Profit before tax | 36.04 | 50.53 | −28.7% | 42.34 | −14.9% |
| Net profit for the period | 29.23 | 36.53 | −20.0% | 31.47 | −7.1% |
| Attributable to shareholders of the company | 29.14 | 36.41 | −20.0% | 31.36 | −7.1% |
| EPS, basic (₹) | 5.69 | 7.11 | −20.0% | 6.11 | −6.9% |
| Net margin (%) | 8.5 | 11.0 | 9.8 |
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 311.95 | 292.27 | +6.7% | 296.88 | +5.1% |
| Other income | 7.60 | 2.02 | +276.2% | 3.03 | +150.5% |
| Total income | 319.55 | 294.29 | +8.6% | 299.91 | +6.5% |
| Profit before tax | 28.64 | 45.05 | −36.4% | 36.80 | −22.2% |
| Net profit for the period | 23.85 | 31.78 | −25.0% | 27.40 | −13.0% |
| EPS, basic (₹) | 4.65 | 6.21 | −25.1% | 5.35 | −13.1% |
| Net margin (%) | 7.6 | 10.9 | 9.2 |
Consolidated
- Filed with BSE
- 13 May 2025, 21:53 IST
- Board meeting
- 13 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 13 May 2025, 21:53 IST
- Board meeting
- 13 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Audited
- Source
- XBRL filing on BSE